Post Type Archives: News

The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committee. Stephen brings […]

ImmuneOncia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-oncology, and Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today that the companies signed a manufacturing agreement for late-stage clinical supply of Danburstotug (IMC-001). Danburstotug is a fully human monoclonal antibody designed as an immune checkpoint inhibitor targeting the programmed […]

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of its Media Development Lab at its Singapore site. The offering aims to support bioprocessing customers in optimizing their media formulations and facilitating a smooth transition to GMP manufacturing, helping reduce scale-up risk and strengthening long-term supply readiness. As […]

Kindeva, a global CDMO and drug delivery innovator, commemorates 70 years today, since the invention of the pressurized metered dose inhaler (pMDI), a breakthrough therapy that transformed respiratory care across the globe. Marking this momentous milestone, the device’s inventors, Kindeva alumni George Maison, Irving Porush and Charles Thiele will be officially inducted into the ‘National […]

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck, known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under […]

Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), has announced the appointment of Susanne Back as Head of In Vivo Pharmacology, further strengthening its bioscience leadership and reinforcing its commitment to delivering high-quality, integrated drug discovery solutions for customers worldwide. Susanne brings 20 years of in vivo pharmacology experience across academia and […]

At this year’s DCAT Week, Olon is outlining its 2026 development plan, aimed at expanding capabilities across its global network, including the United States, India, Italy, and France, through targeted investments and infrastructure upgrades. The plan focuses on capacity expansion, technology enhancement, and increased operational flexibility across multiple sites. In the United States, efforts focus […]

Indena, the Italian global leader in the pharmaceutical industry and in CDMO services for high-quality active pharmaceutical ingredients, is proud to announce its participation at DCAT Week 2026 (March 23-26, 2026, New York), where it will highlight its significantly expanded capabilities in Highly Potent Active Pharmaceutical Ingredients (HPAPIs), Antibody-Drug Conjugates (ADCs), and advancements in Peptide […]

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, announced the second phase of its CDMO growth strategy, committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado. The investment follows the company’s previously announced $6 million expansion […]

SK pharmteco announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors. SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for […]